Here are the 8-K filings from Adia Med Inc (ADIA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow ADIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADIA filings page.
Adia Med, Inc. sold seven membership units in Adia Labs LLC to its Chief Executive Officer, Larry A. Powalisz, for an aggregate purchase price of $350,000, payable entirely in cash. The units represent a 7% membership interest and carry 7% of Adia Labs’ total voting power, assuming 100 issued units and no other units are issued or transferred at closing; economic ownership follows the units.
The agreement requires the Company’s operating agreement to be amended at closing to reflect the units and voting power. The purchase price may be used for Company or Seller corporate purposes only as jointly approved in writing by independent directors Monica Sher, M.D., and Richard Edwards, D.O. Powalisz has no unilateral authority to approve, direct, or decide how the purchase price is used.
Adia Med, Inc. (ADIA) repaid and discharged its unsecured revolving line of credit on October 9, 2026, paying lender Larry Powalisz, the company’s chief executive officer and a related party, a total of $934,970.94. Payments were $500,000 on October 7 and $434,970.94 on October 9; the latter included $74,658.94 in accrued interest, with the balance applied to principal. The lender acknowledged that all outstanding principal and accrued interest were paid in full as of October 9, 2026.
The facility was entered into on June 30, 2024, with Powalisz as lender and the company and its relevant subsidiaries, as applicable, as borrowers. Its commitment had increased over time to $1,000,000, and it bore interest at 6% per annum, calculated daily. The company stated that the facility was satisfied in full for amounts owing through October 9, 2026.
ADIA, identified in the report as Adia Med, Inc. (formerly Adia Nutrition, Inc.), completed the sale of 30 of Adia Labs LLC’s 100 outstanding membership units, representing 30%, to Live Oak Health LLC, doing business as QCM Biologics, for $1.5 million. Consideration is $1 million in cash and a $500,000 promissory note. The note bears 7% annual interest on unpaid principal, with interest-only monthly payments of $2,916.67 for 48 months; the $500,000 principal plus accrued interest is due 48 months after closing.
After closing, ADIA owns 70% of Adia Labs’ units and the buyer owns 30%, but each has 50% of the voting power. ADIA granted the buyer an option to purchase up to 10 additional units for $50,000 each, exercisable in whole units through September 30, 2028. After expenses, taxes and required tax distributions, 10% of the remaining amount is reserved and the other 90% is distributed according to unit ownership within 30 days after quarter-end. ADIA may use the $1 million cash proceeds for Adia Labs or corporate purposes determined by its board.
Adia Nutrition, Inc. (ADIA) has engaged Lucosky Brookman LLP as legal counsel to support a planned uplisting from the OTC Markets to the Nasdaq Capital Market or a similar senior exchange and to advise on a contemplated bridge financing transaction. Under an engagement letter dated August 14, 2026, the firm will handle preparation and filing of a Form S-1 registration statement, related SEC comment responses and amendments, the listing application, and structuring and documentation of the bridge financing, as well as related corporate matters.
Fees for these uplist and bridge financing services are fixed at $150,000, with additional amounts payable if hourly billings exceed 115% of that fee. The fee is scheduled as $30,000 at closing of the bridge financing, $50,000 upon filing the Form S-1, and the balance (plus any excess hourly amounts) at the uplisting closing. After listing on Nasdaq or the New York Stock Exchange, ongoing Exchange Act and related securities work will be billed at $8,000 per month, with other work at stated hourly rates. The firm receives expense reimbursement, customary indemnification, and a security interest in the company’s assets to secure outstanding obligations, and the agreement may be terminated by either party with written notice, subject to payment of amounts due.
Adia Nutrition, Inc. reports a corporate name change to Adia Med, Inc. The company filed a Certificate of Amendment in Nevada on June 2, 2026, changing its legal name and updating its Amended and Restated Articles of Incorporation, with no other changes to articles or bylaws.
Regulatory approval of the name change from FINRA was received on July 10, 2026. Common stock continues to trade on the OTC Markets Venture Market under the ticker “ADIA”, and existing stock certificates remain valid and do not need to be exchanged. Future reports will use the new corporate name Adia Med, Inc.